-
公开(公告)号：US20220380425A1
公开(公告)日：2022-12-01
申请号：US17624114
申请日：2020-07-04
IPC分类号： C07K14/515 , A61P1/16 , A61K39/00
摘要： The present invention relates to a vaccine capable to induce the formation of antibodies directed to angiopoietin-like 3 in vivo. More specifically, the present invention relates to a use of a vaccines which are able to influence the angiopoietin-like 3 mediated immune response for the treatment of liver diseases such as non-alcoholic steatohepatitis and non-alcoholic fatty liver disease and hyperlipidaemia, hypercholesterolemia, or atherosclerosis including the complications lead to the cardiovascular diseases (CVD) which causes morbidity and mortality.
-
公开(公告)号：US20220175721A1
公开(公告)日：2022-06-09
申请号：US17430381
申请日：2020-02-12
发明人： Mukul Jain , Deven V. Parmar , Amit Joharapurkar
IPC分类号： A61K31/40
摘要： Present invention provides the method of treating polycystic ovarian syndrome using compound of formula (I) or pharmaceutically acceptable salt thereof, preferably it provides method of treating polycystic ovarian syndrome in the patient diagnosed with NAFLD. Invention also provides a pharmaceutical composition comprising compound of formula (I) for treatment of polycystic ovarian syndrome, wherein compound of formula (I) is
-
公开(公告)号：US20220023262A1
公开(公告)日：2022-01-27
申请号：US17383930
申请日：2021-07-23
发明人： Kumar Kamlesh SINGH , Sanjay Jagdish DESAI , Piyush Rajendra SHARMA , Daya Ram PAL , Sanjeev Kumar TRIPATHI , Mayur Ramnikbhai PATEL
IPC分类号： A61K31/4025 , A61K31/336
摘要： The present invention relates to a composition comprising high purity pyrrole derivative and method for preparation thereof. The present invention particularly relates to compositions comprising Saroglitazar magnesium having purity of 99.0% or more, and one or more of an aldehyde compound of Formula (II), diketo oxirane compound of Formula (III), hydroxy methyl compound of Formula (IV) or dimer compound of Formula (V), relative to saroglitazar magnesium, each present in an amount of about 0.15% or less, respectively, by weight, when measured by area percentage of HPLC.
-
公开(公告)号：US11110073B2
公开(公告)日：2021-09-07
申请号：US15933937
申请日：2018-03-23
发明人： Sushilkumar Dhanaji Patil , Nirav Ishwarlal Khatri , Alex Kochukunju George , Sushrut Krishnaji Kulkarni
IPC分类号： A61K31/196 , A61K9/00 , A61K45/06 , A61K47/32 , A61K9/08
摘要： The present invention relates to a stable, aqueous, injectable solution comprising diclofenac and polyvinylpyrrolidone. The present invention also relates to processes for preparing the injectable solution.
-
公开(公告)号：US10925871B2
公开(公告)日：2021-02-23
申请号：US15121514
申请日：2015-02-25
发明人： Brij Khera , Muthaiyyan Essakimuthu Kannan , Jitendra Rameshchandra Patel , Saurin Mukundbhai Amin
IPC分类号： A61K31/4985 , A61K9/20 , A61K47/12 , A61K9/16
摘要： The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof.
-
公开(公告)号：US20200179339A1
公开(公告)日：2020-06-11
申请号：US16704447
申请日：2019-12-05
发明人： Mukul R. JAIN , Abhijit CHATTERJEE , Kaushik BANERJEE , Jaideep SINGH , Sunita SINGH , Jitendrakumar PATEL
IPC分类号： A61K31/4015 , A61K31/4025 , A61K31/196 , A61K9/06 , A61K47/38 , A61K47/10 , A61K47/18 , A61K47/22 , A61K47/12 , A61P17/00
摘要： The present invention provides a combination of PDE4 inhibitors or pharmaceutically acceptable salts thereof along with at least one secondary therapeutic agent. The present invention also provides process for the preparation of topical pharmaceutical composition of said combination with one or more pharmaceutically acceptable excipients. The present invention further relates to use of topical pharmaceutical composition for the treatment of atopic dermatitis.
-
公开(公告)号：US20190275102A1
公开(公告)日：2019-09-12
申请号：US16292417
申请日：2019-03-05
发明人： Kannan Essakimuthu MUTHAIYYAN , Debjani Manoj SINGH , Nirav Ishwarlal KHATRI , Omprakash Ganesh Ram SHARMA
摘要： The present invention relates to sterile injectable compositions comprising carfilzomib and one or more phospholipids. The present invention also relates to processes for preparing the sterile injectable compositions.
-
公开(公告)号：US20190177309A1
公开(公告)日：2019-06-13
申请号：US16274352
申请日：2019-02-13
IPC分类号： C07D409/14 , C07D333/54 , C07D247/02 , A61K31/496 , C07D401/12 , A61K9/14
CPC分类号： C07D409/14 , A61K9/14 , A61K31/496 , B01D9/02 , C07D247/02 , C07D333/54 , C07D401/12 , C07D409/12 , C07D487/10
摘要： The present invention relates to Brexpiprazole having a purity of about 99.5% or more by area percentage of HPLC, having total impurities not more than 0.5% relative to brexpiprazole as measured by area percentage of HPLC, and having less than 0.1% 1-(benzo[b]thiophen-4-yl)piperazine or a salt thereof relative to brexpiprazole by area percentage of HPLC. The present invention also provides a composition comprising brexpiprazole having 1-(benzo[b]thiophen-4-yl)-piperazine or a salt thereof in an amount less than about 0.1% relative to brexpiprazole by area percentage of HPLC and process for the preparation of brexpiprazole.
-
公开(公告)号：US20180346486A1
公开(公告)日：2018-12-06
申请号：US16002007
申请日：2018-06-07
IPC分类号： C07D513/04 , C07F3/00 , A61K31/40 , C07D209/44 , C07D295/096 , C07D491/048 , C07D207/06 , C07D209/12 , C07D498/04 , C07D495/04 , C07D207/20 , C07D207/08 , C07D491/04 , C07D487/04 , C07D471/04 , C07D217/04 , C07D215/20 , C07D215/06 , A61K31/519 , A61K31/4985 , A61K31/472 , A61K31/47 , A61K31/439 , A61K31/437 , A61K31/4365 , A61K31/4162 , A61K31/407 , A61K31/404 , C07D491/08 , A61K31/496 , A61K31/4453 , A61K31/4375 , A61K31/435 , C07D209/08
CPC分类号： C07D513/04 , A61K31/40 , A61K31/404 , A61K31/407 , A61K31/4162 , A61K31/435 , A61K31/4365 , A61K31/437 , A61K31/4375 , A61K31/439 , A61K31/4453 , A61K31/47 , A61K31/472 , A61K31/496 , A61K31/4985 , A61K31/519 , C07D207/06 , C07D207/08 , C07D207/20 , C07D209/08 , C07D209/12 , C07D209/44 , C07D215/06 , C07D215/20 , C07D217/04 , C07D295/096 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/048 , C07D491/08 , C07D495/04 , C07D498/04 , C07F3/00
摘要： The present invention relates to a compound (3S)-3-(4-((3-(6-Oxa-3-azabicyclo [3.1.1]heptan-3-ylmethyl)benzyl)oxy)phenyl)hex-4-ynoic acid methods for use of this and other compounds.
-
公开(公告)号：US10098868B2
公开(公告)日：2018-10-16
申请号：US15475812
申请日：2017-03-31
摘要： The present invention relates to the stable pharmaceutical composition of a suitable hypolipidemic agent. Preferably, the present invention discloses novel formulations of the compound of formula (I), or pharmaceutically acceptable salts of compounds of formula (I). More particularly the present invention relates to the stable pharmaceutical composition of compounds of formula (I) comprising compounds of formula (I) or its pharmaceutically acceptable salts, wherein the pH of the formulation is maintained above 7. formula (I).
-
-
-
-
-
-
-
-
-
搜索结果
200 条记录 (耗时 0.019 秒)
